Skip NavigationSkip to Content
Return Return to Search Results

Fumarate hydratase enzyme activity in lymphoblastoid cells and fibroblasts of individuals in families with hereditary leiomyomatosis and renal cell cancer

  1. Author:
    Pithukpakorn, M.
    Wei, M. H.
    Toure, O.
    Steinbach, P. J.
    Glenn, G. M.
    Zbar, B.
    Linehan, W. M.
    Toro, J. R.

  2. Author Address

    NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, Rockville, MD 20892 USA. NHGRI, Med Genet Branch, NIH, Bethesda, MD 20892 USA. SAIC Frederick Inc, Program Div Canc Epidemiol & Genet, Frederick, MD USA. NCI, Urol Oncol Branch, Canc Res Ctr, NIH, Bethesda, MD 20892 USA.;Toro, JR, NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, 6120 Execut Blvd,Execut Plaza S,Room 7012, Bethesda, MD 20892 USA.;toroj@mail.nih.gov
    1. Year: 2006
    2. Date: Sep
  2. Journal: Journal of Medical Genetics
    1. 43
    2. 9
    3. Pages: 755-762
  4. Type of Article: Article
  5. ISSN: 0022-2593
  1. Abstract:

    Background: Hereditary leiomyomatosis and renal cell cancer (HLRCC) is the autosomal dominant heritable syndrome with predisposition to development of renal cell carcinoma and smooth muscle tumours of the skin and uterus. Objective: To measure the fumarate hydratase (FH) enzyme activity in lymphoblastoid cell lines and fibroblast cell lines of individuals with HLRCC and other familial renal cancer syndromes. Methods: FH enzyme activity was determined in the whole cell, cytosolic, and mitochondrial fractions in 50 lymphoblastoid and 16 fibroblast cell lines including cell lines from individuals with HLRCC with 16 different mutations. Results: Lymphoblastoid cell lines (n = 20) and fibroblast cell lines (n = 11) from individuals with HLRCC had lower FH enzyme activity than cells from normal controls (p < 0.05). The enzyme activity in lymphoblastoid cell lines from three individuals with mutations in R190 was not significantly different from individuals with other missense mutations. The cytosolic and mitochondrial FH activity of cell lines from individuals with HLRCC was reduced compared with those from control cell lines (p < 0.05). There was no significant difference in enzyme activity between control cell lines (n = 4) and cell lines from affected individuals with other hereditary renal cancer syndromes (n = 22). Conclusions: FH enzyme activity testing provides a useful diagnostic method for confirmation of clinical diagnosis and screening of at- risk family members.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1136/jmg.2006.041087
  3. View record in Web of Science®
  4. WOS: 000240239400009

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel